1. A method of treating a disease associated with target cells expressing CD138, comprising: administering to a patient in need an effective amount of an immunoconjugate containing at least one targeting agent, the targets of which are cells expressing CD138, and at least one effector molecule, wherein said targeting agent operably linked to said effector molecule to form said immunoconjugate, and wherein said effective amount is an acceptable amount. 2. The method according to claim 1, wherein the immunoconjugate is administered to an individual in an amount of 5-200 mg / mile pharmacokinetically equivalent to 5-200 mg / m when administered in combination with an agent for treating adverse side effects. The method according to claim 1 or 2, where the maximum concentration of immunoconjugate in an individual’s plasma between 0 and 2 hours after completion of the first administration is less than 50%, preferably less than 40%, more preferably less than 30%, even more preferably less than 20% or even less than 10 % of theoretical maximum concentration of the indicated immunoconjugate. 4. The method according to claim 3, in which the immunoconjugate is administered at least four times, and the maximum concentration of the immunoconjugate in an individual's plasma between 0 and 2 hours after completion of each of these administrations is less than 55%, more preferably less than 50%, more preferably less than 40%, even more preferably, less than 30%, less than 20%, or even less than 10% of the theoretical maximum concentration of said immunoconjugate. 5. The method according to claim 1, where the specified immunoconjugate is administered in a dose, preferably in a repeated single dose of not more than pr1. Способ лечения заболевания, связанного с клетками-мишенями, экспрессирующими CD138, предусматривающий:введение нуждающемуся пациенту эффективного количества иммуноконъюгата, содержащегопо крайней мере один нацеливающий агент, мишенями которого являются клетки, экспресс
